Highest-materiality recent filing
STERIS FY26 revenue $5.9B (+9%), adj EPS $10.17; FY27 guidance adj EPS $11.10-$11.30
Full year revenue from continuing ops $5.9B (+9%), constant currency organic +7%; adjusted EPS $10.17 vs $9.22.
STERIS appoints Pierre Boulud to board; Richard Breeden to retire at 2026 AGM
Richard C. Breeden notified he will not stand for reelection at 2026 AGM; retirement not due to any disagreement.
STERIS extends former CFO Tokich's advisory role through March 2027 with reduced pay
Michael Tokich's senior financial advisor role extended part-time from April 1, 2026 to March 31, 2027.
STERIS Q3 revenue +9% to $1.5B; adj EPS $2.53 beats prior year $2.32; FY2026 outlook maintained
Revenue $1.5B (+9% YoY); constant currency organic revenue growth 8%.
STERIS Q2 FY2026 revenue up 10% to $1.5B; adjusted EPS $2.47; raises FY outlook
Q2 revenue $1.5B (+10% YoY); constant currency organic revenue +9%.
STERIS Q1 adj EPS $2.34 vs $2.03; revenue +9%; FY revenue guidance raised
Q1 revenue $1.4B (+9% as reported, +8% organic constant currency); adj EPS $2.34 vs $2.03.
STERIS director Richard Steeves to retire from board at July 31 annual meeting
Dr. Richard Steeves notified STERIS of retirement effective at July 31, 2025 Annual General Meeting.
STERIS reports fiscal 2025 adjusted EPS $9.22, revenue $5.5B; guides FY2026 EPS $9.90-$10.15
Full-year revenue from continuing ops +6% to $5.5B; constant currency organic growth 6%.
STERIS subsidiary Isomedix settles EO personal injury claims for up to $48.15M
Up to $48.15M settlement for substantially all pending EO injury claims in Cook County, IL.
STERIS Q3 EPS $2.32 (+11% YoY); revenue $1.4B (+6%); guidance trimmed on currency
Adjusted EPS of $2.32 vs $2.09 YoY; GAAP EPS $1.75 vs $1.49; revenue $1.4B (+6% as reported, +6% organic constant currency)
STERIS Q2 adjusted EPS $2.14, revenue $1.3B (+7%); reiterates FY2025 outlook
Adjusted EPS from continuing operations $2.14 vs $1.86 prior year; as-reported EPS $1.51 vs $1.20.
STERIS enters new $1.1B revolver, replaces 2021 credit facility, matures Oct 2029
New $1.1B revolving credit facility replaces the March 2021 credit agreement; proceeds for general corporate purposes.
STERIS Q1 FY2025 revenue $1.3B (+8%), adjusted EPS $2.03; guidance reiterated
Total revenue from continuing ops $1.3B, up 8% YoY; constant currency organic revenue up 6%.
STERIS reports 2024 AGM results; all director nominees elected, say-on-pay approved
Quorum of 93.55% (92.5M of 98.9M shares) present at August 1, 2024 AGM.
STERIS closes sale of Dental business to HuFriedy Group for $787.5M
Transaction closed on May 31, 2024; base purchase price $787.5M plus up to $12.5M contingent payment.
Q4 revenue $1.5B (+10% YoY); Q4 GAAP net loss $1.4M (-$0.01/sh) vs $187.2M profit in prior year.
STERIS to sell Dental segment to Peak Rock Capital for $787.5M cash, plus earnout
Purchase price $787.5M cash (subject to adjustments) plus up to $12.5M earnout on FY2025 revenue targets.
STERIS Q3 revenue rises 15% to $1.40B, adjusted EPS $2.22, outlook updated
Revenue $1.40B, +15% as reported; constant currency organic revenue +10%.
STERIS board adopts annual say-on-pay frequency per shareholder advisory vote
Non-binding shareholder vote at July 27, 2023 AGM favored annual say-on-pay frequency.
STERIS reports Q2 FY2024 revenue $1.34B, up 12%; EPS $1.16, adjusted $2.03
Revenue of $1.34B increased 12% as reported and 8% constant currency organic from $1.20B in Q2 FY2023.
STERIS Q1 revenue $1.28B (+11% YoY), adj. EPS $2.00, GAAP EPS $1.25
Revenue of $1.28B, up 11% as reported and constant currency organic.
STERIS appoints Dr. Esther Alegria to board committees
Dr. Alegria appointed to Compliance and Technology Committee and Nominating and Governance Committee effective July 27, 2023.
STERIS plc reports results of 2023 Annual General Meeting; all proposals passed
Quorum of 91.7M shares (92.97% of outstanding) present at the July 27, 2023 meeting.
STERIS acquires surgical instrumentation assets from BD for $540M; expects close by Sept 30, 2023
Purchase price $540M in cash; assets include V. Mueller, Snowden-Pencer, Genesis brands.
STERIS reports Q4 revenue $1.38B (+14%), adjusted EPS $2.30; FY2024 outlook provided
Q4 revenue $1.38B, up 14% YoY; constant currency organic revenue growth 16%.
STERIS appoints Esther Alegria to Board of Directors effective May 3, 2023
Board size increased to ten members; Dr. Alegria, age 64, appointed immediately.
STERIS Q3: Revenue $1.22B (+1% as reported, 7% constant currency organic), adj EPS $2.02
Revenue $1.22B, up 1% as reported; constant currency organic revenue growth 7%.
STERIS reports flat Q2 revenue, adjusted EPS $1.99, $490.6M dental impairment
Revenue flat at $1.2B; constant currency organic revenue grew 7% YoY.
STERIS Q1 FY2023 revenue up 19% to $1.2B; adjusted EPS $1.90
Revenue $1.2B, up 19% YoY; constant currency organic revenue up 6%.
STERIS shareholders re-elect all nine directors; say-on-pay approved at AGM
All nine director nominees elected; Jacqueline B. Kosecoff received 50.3M for, 36.9M against.
STERIS Q4 revenue up 39% to $1.2B; adj. EPS $2.04; provides FY23 outlook
Q4 revenue $1.2B, up 39% as reported from $873.5M; constant currency organic growth 11%.
STERIS Q3 FY2022 revenue $1.2B (+49% as reported); adjusted EPS $2.12; FY22 outlook raised
Revenue $1.2B (+49% as reported; +9% constant currency organic) vs $808.9M in Q3 FY2021
STERIS closes sale of Renal Care business to Evoqua Water Technologies for $196M
Closed sale of Renal Care business to Evoqua Water Technologies on Jan 3, 2022 for ~$196M cash.
STERIS to sell Renal Care business to Evoqua Water Technologies for ~$196M cash
Cash consideration of approximately $196 million, subject to customary working capital and other adjustments.
STERIS Q2 FY2022 revenue $1.197B (+58% as reported); adj. EPS $1.99
Revenue $1.197B, +58% as reported vs $756M prior year; constant currency organic growth +12%.
STERIS Q1 revenue rises 45% to $968.4M; raises outlook and dividend
Revenue $968.4M, up 45% as reported vs. $668.9M in Q1 FY21; constant currency organic revenue up 21%.
STERIS plc appoints Paul E. Martin to two board committees
Paul E. Martin appointed to Compliance and Technology Committee on July 29, 2021.
STERIS shareholders re-elect all 9 director nominees and approve auditor at 2021 AGM
All 9 director nominees re-elected; Dr. Jacqueline B. Kosecoff received lowest support (58.2M for, 14.8M against).
On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders.
On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date.
The Board of Directors (the “Board”) of STERIS plc (the “Company”) increased its size from nine to ten members on May 3, 2023, and elected Dr. Esther Alegria to serve as a director effective as of that date.
Max materiality 0.90 · Median 0.68 · Most common event earnings